大立科技(002214) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥101,120,520.76, a decrease of 33.46% compared to the same period last year[5] - The net profit attributable to shareholders was -¥9,333,294.98, representing a decline of 120.08% year-over-year[5] - The net profit after deducting non-recurring gains and losses was -¥17,384,157.97, down 140.02% compared to the previous year[5] - The company's operating revenue for the current period was CNY 741.40 million, a decrease of 9.37% compared to CNY 818.09 million in the same period last year[27] - Revenue from epidemic prevention products dropped significantly by 98.18% to CNY 9.75 million, while non-epidemic prevention product revenue surged by 161.22% to CNY 729.08 million[27] - Net profit attributable to the parent company was ¥250,845,311.53, down 26.0% from ¥338,806,332.81 year-over-year[57] - Basic and diluted earnings per share were both ¥0.42, compared to ¥0.74 in the previous year[61] Cash Flow - The company reported a net cash flow from operating activities of -¥79,387,591.61, a decrease of 130.90% year-to-date[5] - The net cash flow from operating activities decreased by CNY 336.27 million compared to the previous year, mainly due to a reduction in cash received from sales and an increase in payments to employees and taxes[23] - The net cash flow from investing activities decreased by CNY 350.03 million compared to the previous year, primarily due to cash management of temporarily idle raised funds[23] - The net cash flow from financing activities increased by CNY 1,039.66 million compared to the previous year, mainly due to funds raised from a private placement of shares[23] - Cash flow from operating activities was ¥404,590,241.04, a significant decrease from ¥852,864,937.08 in the same period last year[62] - The net cash flow from operating activities was -79,387,591.61, a significant decrease compared to 256,878,263.99 in the previous period, indicating a decline in operational performance[65] - Total cash inflow from financing activities reached 973,670,602.88, compared to 284,671,480.00 in the previous period, showing a strong increase in financing efforts[68] - The net cash flow from investing activities was -439,758,877.51, a notable decline from -89,727,264.58 in the previous period, reflecting increased investment expenditures[65] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,961,381,647.44, an increase of 59.77% from the end of the previous year[7] - The total assets increased to ¥2,961,381,647.44 from ¥1,853,512,354.10 year-over-year[52] - The company's total liabilities decreased from RMB 363,933,113.04 to RMB 338,378,401.35, reflecting improved financial health[50] - Total liabilities amounted to ¥347,493,084.27, down from ¥403,831,155.92 year-over-year[52] - The company's cash and cash equivalents increased to RMB 694,698,442.72 from RMB 140,697,807.23 year-over-year[47] - Accounts receivable rose to RMB 1,019,536,952.06 from RMB 621,742,934.61 year-over-year, indicating a significant increase in sales or credit terms[47] Shareholder Information - The total number of common shareholders at the end of the reporting period was 31,378, with the largest shareholder holding 26.73% of the shares[29] - The company raised a total of CNY 959.29 million from a private placement of shares, net of issuance costs[35] - The total share capital increased from 499,925,704 shares to 599,237,935 shares following a rights distribution and capital reserve conversion[36] - The company approved a share repurchase plan with a total fund of no less than RMB 50 million and no more than RMB 100 million, with a maximum repurchase price of RMB 14.80 per share[37] - As of December 31, 2020, the company repurchased a total of 3,364,548 shares, accounting for 0.73% of the total share capital, with a total amount of RMB 70,104,403.76[42] Research and Development - Research and development expenses increased by ¥21,752,000, a growth of 27.10% compared to the same period last year[20] - Research and development expenses rose to ¥102,026,911.09, up from ¥80,274,906.00 in the same period last year[57] Strategic Initiatives - The company signed a strategic cooperation agreement with the Northern Night Vision Technology Research Institute Group to establish a joint venture for the research and production of vanadium oxide uncooled infrared detectors[43] - A cooperation framework agreement was signed with the Changchun Institute of Optics, Fine Mechanics and Physics to jointly establish a joint venture for optoelectronic equipment project research and development[44] Future Outlook - The company expects a significant change in its business structure for the full year, with non-epidemic prevention product revenue expected to increase significantly[28] - The company anticipates rapid recovery in civilian product revenue as the pandemic eases, particularly in the "new infrastructure" sector where demand is expected to grow significantly[28]